CVS Health Corporation $CVS Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its position in CVS Health Corporation (NYSE:CVS) by 2.4% in the 1st quarter, HoldingsChannel reports. The firm owned 2,799,884 shares of the pharmacy operator’s stock after selling 68,340 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in CVS Health were worth $201,088,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in CVS. Hamlin Capital Management LLC purchased a new stake in CVS Health during the fourth quarter worth $160,844,000. Capitolis Liquid Global Markets LLC acquired a new position in CVS Health in the 3rd quarter worth about $11,308,000. National Bank of Canada FI boosted its position in CVS Health by 50.3% during the third quarter. National Bank of Canada FI now owns 1,770,840 shares of the pharmacy operator’s stock worth $133,495,000 after purchasing an additional 593,015 shares in the last quarter. State Street Corp boosted its position in CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its holdings in CVS Health by 2.9% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 725,189 shares of the pharmacy operator’s stock valued at $57,551,000 after purchasing an additional 20,217 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research reports. Morgan Stanley boosted their target price on shares of CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Royal Bank Of Canada raised their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Wall Street Zen raised shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Cantor Fitzgerald raised their price target on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday. Twenty-one research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $102.84.

CVS Health Stock Down 1.7%

CVS Health stock opened at $102.69 on Friday. The stock’s fifty day moving average is $96.50 and its two-hundred day moving average is $84.03. The stock has a market cap of $131.03 billion, a PE ratio of 45.24, a P/E/G ratio of 1.02 and a beta of 0.61. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $106.15. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the prior year, the company posted $2.25 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

Insider Activity

In other news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS drew bullish attention after Jim Cramer highlighted health insurance/managed care as a strong sector and called CVS one of the biggest winners as Walgreens fades, reinforcing the market’s view that CVS may benefit from industry consolidation. Cramer’s Stop Trading: CVS Health
• Positive Sentiment: CVS CEO comments that Aetna has medical costs “under control” ahead of second-quarter earnings suggest margin pressure may be manageable, which could support investor confidence going into results. CVS CEO says Aetna has a handle on medical costs in advance of Q2 earnings
• Positive Sentiment: Heavy call-option buying and multiple articles flagging CVS as a momentum/trending stock point to increased trader interest and possible speculation on further upside. Here’s Why CVS Health (CVS) is a Strong Momentum Stock
• Neutral Sentiment: CVS also continued to get publicity around its Specialty Pharmacy and HIV-treatment support programs, which helps the company’s long-term image but is unlikely to move the stock immediately. HIV Is Now a Manageable Chronic Condition – How CVS Specialty Helps Patients Start and Stay on Treatment
• Negative Sentiment: A major risk factor is the reported $440 million Justice Department settlement involving CVS and Omnicare, which could weigh on sentiment by reminding investors of legal and regulatory overhangs. CVS, Omnicare reach $440M Justice Department settlement
• Negative Sentiment: A market-wrap note showing CVS trading lower on the day indicates investors are still taking profits or staying cautious ahead of earnings and settlement-related headlines. CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.